Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Rating of "Hold" from Analysts

Key Points

• Moderna, Inc. (NASDAQ:MRNA) has received a consensus rating of "Hold" from 22 brokerages, with 4 sell ratings, 14 hold ratings, 3 buy ratings, and 1 strong buy rating.
• The average one-year price target among brokers covering Moderna is $41.81, indicating potential for price appreciation.
• Despite its challenges, Moderna recently posted a quarterly earnings result of ($2.13) per share, beating the consensus estimate and achieving revenue of $142 million, although this reflects a 41.1% year-over-year decline.

Shares of Moderna, Inc. (NASDAQ:MRNA - Get Free Report) have been assigned a consensus rating of "Hold" from the twenty-two brokerages that are currently covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a sell recommendation, fourteen have assigned a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $41.8125.

A number of equities analysts recently commented on MRNA shares. William Blair reissued a "market perform" rating on shares of Moderna in a research note on Monday, June 2nd. Citigroup began coverage on shares of Moderna in a report on Friday, August 1st. They issued a "neutral" rating and a $40.00 price target on the stock. Bank of America decreased their price objective on shares of Moderna from $26.00 to $25.00 and set an "underperform" rating for the company in a research report on Tuesday, July 22nd. JPMorgan Chase & Co. set a $26.00 price target on shares of Moderna in a research report on Friday, August 1st. Finally, Cowen started coverage on shares of Moderna in a research note on Sunday, July 13th. They set a "hold" rating for the company.

Institutional Trading of Moderna

Several hedge funds have recently made changes to their positions in MRNA. Parkside Financial Bank & Trust boosted its position in shares of Moderna by 19.0% during the 2nd quarter. Parkside Financial Bank & Trust now owns 2,347 shares of the company's stock worth $65,000 after purchasing an additional 375 shares during the period. Probity Advisors Inc. boosted its position in shares of Moderna by 2.6% during the 2nd quarter. Probity Advisors Inc. now owns 14,892 shares of the company's stock worth $411,000 after purchasing an additional 377 shares during the period. Deseret Mutual Benefit Administrators boosted its position in shares of Moderna by 53.3% during the 1st quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock worth $32,000 after purchasing an additional 392 shares during the period. Amalgamated Bank boosted its position in shares of Moderna by 0.6% during the 2nd quarter. Amalgamated Bank now owns 65,458 shares of the company's stock worth $1,806,000 after purchasing an additional 408 shares during the period. Finally, Rothschild Investment LLC boosted its position in shares of Moderna by 94.1% during the 2nd quarter. Rothschild Investment LLC now owns 920 shares of the company's stock worth $25,000 after purchasing an additional 446 shares during the period. Hedge funds and other institutional investors own 75.33% of the company's stock.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $23.51 on Friday. The company has a market cap of $9.15 billion, a P/E ratio of -3.12 and a beta of 1.93. Moderna has a 1 year low of $23.15 and a 1 year high of $75.37. The firm has a 50-day simple moving average of $28.34 and a two-hundred day simple moving average of $28.17.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, beating the consensus estimate of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The firm had revenue of $142.00 million during the quarter, compared to the consensus estimate of $116.26 million. During the same quarter in the previous year, the firm posted ($3.33) earnings per share. The company's revenue was down 41.1% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Moderna will post -9.61 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.